AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far.

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune Partner Life Molecular Imaging Initiates Phase 3 S tudy of Tau PET Diagnostic PI - 2620 for Alzheimer's Disease

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners.

Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket

AC Immune 's Alzheimer's Disease Vaccine-candidate ACI-35.030 S elect ed for Further Development

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.

AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies London Healthcare Conference, which is taking place from November 15 – 17, 2022.

AC Immune to Present at the Jefferies London Healthcare Conference

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

LAUSANNE, Switzerland, Oct. 28, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the third quarter ended September 30, 2022, and provided a corporate update.

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-emission tomography (PET) tracer, into late-stage clinical development in Alzheimer's disease (AD). As part of the agreement with AC Immune, LMI will make a milestone payment.

AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's Disease

LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today hosted key opinion leader (KOL) Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital and Harvard Medical School, Boston, for a webinar focused on vaccines to treat and prevent Alzheimer's and Parkinson's diseases.

AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer's and Parkinson's Diseases

LAUSANNE, Switzerland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partners presented the first quantitative data from the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial during a Focused Topic Session at the Alzheimer's Association International Conference (AAIC). The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimer's disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer's disease.

Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAIC

LAUSANNE, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the quarter ended June 30, 2022, and provided a corporate update.

AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update

LAUSANNE, Switzerland, July 22, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced 10 upcoming presentations that will be delivered at the Alzheimer's Association International Conference (AAIC) in San Diego, California (United States) and online, July 31 – August 4, 2022.

AC Immune Announces Upcoming Presentations at the Alzheimer's Association International Conference

Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are members of the world's biggest extended family with Autosomal Dominant Alzheimer's Disease, or ADAD, in Colombia.

AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals

Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer's disease

AC Immune Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer's Disease

LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022.

AC Immune to Present at the 2022 Jefferies Healthcare Conference

Two clinical readouts delivered in Q1; five more expected by year-end

AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference, taking place virtually on April 27-28, 2022.

AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

Howard Donovan appointed Chief HR Officer, joins executive committee

AC Immune Reports Changes to Senior Management

Seven clinical data readouts expected in 2022 Three vaccines, targeting Tau, Abeta and alpha-synuclein, advancing in 2022 Semorinemab Phase 2 Lauriet trial: additional fluid biomarker data expected in H2 2022 Initiation of ACI-24 anti-Abeta vaccine Phase 1b/2 trial in patients with Alzheimer's disease (AD) and people living with Down syndrome (DS) expected in H1 2022 AD/PD™ Conference: ACI-12589 identified as a reliable and accurate PET tracer for alpha-synucleinopathies (e.g. MSA) Strong financial position of CHF 198.2 million ensures the Company is fully financed through at least Q1 2024

News for AC Immune Stock (ACIU)